Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.

By F. Pi‐Sunyer, L. Aronne, H. Heshmati, J. Devin, J. Rosenstock, for the RIO-North America Study Group. Journal of the American Medical Association (JAMA), 2006

1,278 citations recorded by the source corpus.

Subfields: Pharmacology, Toxicology

View Paper: https://www.semanticscholar.org/paper/4f12930a6d39a5b320c3df14efaf89a603adfd72

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pharmacology

1. V. Di Marzo
2. George Kunos
3. P. Pacher
4. S. Batkai
5. P. Zimmet

In Toxicology

1. George Kunos
2. V. Di Marzo

Citations in the corpus

• The metabolic syndrome. (2003, positive): “Both the Rimonabant in Obesity-Europe study [61] and the Rimonabant in Obesity-North America study [62] showed that rimonabant induces significant weight loss that can be sustained over a 2-year period.”
• Consensus on infertility treatment related to polycystic ovary syndrome. (2008, background): “regarding the use of rimonabant, which decreases food intake (Pi-Sunyer et al., 2006).”
• The Endocannabinoid System as an Emerging Target of Pharmacotherapy (2006, background): “During the 2nd year, rimonabant-treated patients retained the improvements achieved during the 1st year, whereas those who switched to placebo regained their original weight (Pi-Sunyer et al., 2006).”
• Targeting the endocannabinoid system: to enhance or reduce? (2008, background): “The first such compound, rimonabant, successfully completed four Phase III trial”